{
  "trial_id": "NCT02823626",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "participate in the study. Informed consent will be taken at this time.",
      "label": "met"
    },
    {
      "criterion": "receive intravenous loop diuretic per the discretion of treating physician and will be closely followed for weight loss and symptoms relief.",
      "label": "met"
    },
    {
      "criterion": "Screening: The patients who don't respond as measured by symptoms relief or <0.5 kg weight loss/day",
      "label": "unknown"
    },
    {
      "criterion": "Despite furosemide \u2265 160 mg IV total daily dose or equivalent dose of torsemide or bumetanide.",
      "label": "met"
    },
    {
      "criterion": "will be considered for the study intervention. Patients who have not participated in the pre-screening phase and do not respond adequately to furosemide >160 mg iv daily dose will directly be enrolled into active intervention part of the study.",
      "label": "unknown"
    },
    {
      "criterion": "Intervention (High-Dose Spironolactone + Patiromer): Patients will be initiated on spironolactone 100 mg orally once daily along with patiromer 8.4 gm orally (if serum K >4.3 meq/L).",
      "label": "unknown"
    },
    {
      "criterion": "The dose of loop diuretic will stay same during rest of the study period.",
      "label": "unknown"
    },
    {
      "criterion": "On day 2, the dose of spironolactone will be titrated to 200 mg orally once a day depending on the diuretic response and lab results.",
      "label": "unknown"
    },
    {
      "criterion": "Serum potassium will be monitored twice a day.",
      "label": "unknown"
    },
    {
      "criterion": "The dose of patiromer will be increased to 16.8 gm in patients with potassium levels exceeding 5.5 meq/L; or it will be held for serum K <4.3 mEq/L.",
      "label": "unknown"
    },
    {
      "criterion": "Treatment will continue till patients achieve euvolemia or get discharged.",
      "label": "unknown"
    },
    {
      "criterion": "Euvolemia is defined as resolution of symptoms and signs of volume overload.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Acute coronary syndrome",
      "label": "triggers"
    },
    {
      "criterion": "Patients with a baseline eGFR < 30 ml/min by MDRD equation",
      "label": "unknown"
    },
    {
      "criterion": "Baseline potassium concentration \u2265 5.5 mEq/L",
      "label": "triggers"
    },
    {
      "criterion": "Requirement for intravenous vasodilators or inotropic agents",
      "label": "triggers"
    },
    {
      "criterion": "Systemic infection",
      "label": "triggers"
    },
    {
      "criterion": "Patients with concomitant end-stage liver disease",
      "label": "unknown"
    },
    {
      "criterion": "Hemodynamically significant uncorrected valvular disease",
      "label": "unknown"
    },
    {
      "criterion": "Patients with pulmonary embolism",
      "label": "triggers"
    }
  ],
  "notes": "Patient has V. cholerae in stool, but no fever or blood pressure issues.",
  "_meta": {
    "topic_id": "52",
    "trial_id": "NCT02823626",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}